Britain and America have signed a major bilateral deal that will keep zero tariffs on UK medicine exports going into the American market.
Agreement Details of the Deal
In exchange for the tariff guarantee, the UK has pledged to boost expenditure on pharmaceuticals through the National Health Service (NHS). This pledge secures that import taxes on these vital goods will be held at nothing for a period of the next three years.
This agreement comes after earlier statements to dramatically increase duties on branded pharmaceutical products, with increases discussed as high as 100%.
"This deal between the United Kingdom reinforces the international landscape for new treatments and introduces long-overdue equity to transatlantic pharmaceutical trade," a statement declared.
Trade Impact
Drugs represent one of the UK's largest exports to the America, which is by far the biggest market for large companies like GSK and AstraZeneca.
Export figures reveal that in the one-year period to the end of last September, the UK sold medicines totaling £11.1bn to the US. This figure represented a significant portion of all goods exports in that span.
"This agreement safeguards employment, increases investment and sets the stage for the UK to establish itself as a global hub for life sciences," a minister remarked.
Specific British Pledges
The pact involves several key changes from the British government:
- Price Threshold Increase: The UK will lift the cost ceiling at which it judges new medicines to be unaffordable by a quarter.
- Increased NHS Spending: There is a target to increase total health service expenditure on medicines from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
- Rebate Cap: The percentage pharmaceutical firms must pay back to the NHS to prevent overspending will be restricted at 15%. Last year, refunds exceeded 20%.
Recent Tensions
The deal comes amid a ongoing dispute between the drug companies and the ministers over spending levels and NHS adoption.
The disagreement were heightened by assertions that US customers were paying significantly more for the equivalent treatments than consumers in the Britain and the EU.
Recently, several large drug company projects in the UK have been paused or cancelled, while substantial investments have been directed toward projects in the United States.
One official acknowledged that the NHS needed to increase expenditure on treatments, noting that its expenditure on drugs had declined as a proportion of its overall budget over the previous ten-year period.
